ADRB3 Antibody

What are the key properties of commercially available ADRB3 antibodies?

Commercial ADRB3 antibodies are available in various formats, each with distinct properties to suit different experimental applications. Most ADRB3 antibodies are produced in rabbit hosts and are available as both polyclonal and monoclonal formats. The molecular weight of ADRB3 is calculated at approximately 51,990 Da, though the observed molecular weight in experimental conditions typically ranges from 44-50 kDa .

The following table summarizes key properties of typical ADRB3 antibodies:

These antibodies are typically validated for Western blot, immunofluorescence, immunocytochemistry, and ELISA applications, with reactivity against human, mouse, and rat samples depending on the specific product .

How should ADRB3 antibodies be stored and handled to maintain reactivity?

ADRB3 antibodies require proper storage and handling to maintain optimal reactivity and prevent degradation. Most commercial ADRB3 antibodies are supplied in liquid form containing PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . These should be stored at -20°C, where they typically remain stable for one year after shipment. For antibodies supplied in this formulation, aliquoting is generally unnecessary for -20°C storage. Some products in smaller volumes (e.g., 20μl) may contain 0.1% BSA as a stabilizer .

When working with these antibodies, it's essential to avoid repeated freeze-thaw cycles. Bring the antibody to room temperature before opening the vial, and then keep it on ice during use. When returning to storage, ensure the cap is tightly sealed to prevent evaporation and contamination. For diluted working solutions, prepare only the amount needed for immediate use as diluted antibodies may lose activity over time. Always wear gloves when handling antibodies to prevent contamination with proteases from skin .

What are the optimal conditions for Western blot analysis using ADRB3 antibodies?

For optimal Western blot analysis using ADRB3 antibodies, researchers should follow a protocol similar to that validated in the literature. Based on experimental data, electrophoresis should be performed on 5-20% SDS-PAGE gels at 70V (stacking gel) followed by 90V (resolving gel) for 2-3 hours. Each lane should be loaded with approximately 50μg of protein sample under reducing conditions .

The following protocol has been validated for ADRB3 detection:

• After electrophoresis, transfer proteins to a nitrocellulose membrane at 150mA for 50-90 minutes

• Block the membrane with 5% non-fat milk in TBS for 1.5 hours at room temperature

• Incubate the membrane with rabbit anti-ADRB3 antibody at 0.5 μg/mL (or diluted 1:1000-1:4000) overnight at 4°C

• Wash with TBS-0.1% Tween three times (5 minutes each)

• Probe with goat anti-rabbit IgG-HRP secondary antibody at a dilution of 1:5000 for 1.5 hours at room temperature

• Develop signal using an enhanced chemiluminescent detection kit

Under these conditions, ADRB3 is typically detected at approximately 44kD, which is consistent with its expected molecular weight in most human, rat, and mouse samples .

How can ADRB3 antibodies be optimized for immunofluorescence and immunocytochemistry?

For immunofluorescence and immunocytochemistry applications, ADRB3 antibodies require specific optimization to achieve strong, specific staining while minimizing background. Based on validated protocols, the following methodology is recommended:

For immunofluorescence in cell lines (e.g., A549 cells):

• Fix cells with 4% paraformaldehyde and permeabilize with 0.1% Triton X-100

• Block in PBS containing 2% BSA to reduce non-specific binding

• Incubate with rabbit anti-ADRB3 antibody at 1:200 dilution overnight at 4°C

• For co-staining (e.g., with Ki-67), use different host species antibodies to avoid cross-reactivity

• Incubate with fluorophore-conjugated secondary antibodies (e.g., Alexa Fluor 555 for ADRB3)

• Counterstain nuclei with DAPI

• Analyze using confocal microscopy

For immunocytochemistry in tissue sections:

• Perform standard deparaffinization, rehydration, and antigen retrieval procedures

• For enzymatic antigen retrieval, use IHC enzyme antigen retrieval reagent for 15 minutes

• Block with 10% goat serum to minimize background

• Incubate with ADRB3 antibody at 1:200 dilution for 2 hours

• Visualize using HRP-based detection systems such as DAB substrate

• Score based on staining intensity (light yellow brown = weakly positive; brown = positive; dark brown = strongly positive)

Signal quantification can be performed by calculating the geometric mean fluorescence intensity (MFI) or using a scoring system where 0 = negative, 1 = equivocal/uninterpretable, 2 = weak positive, and 3 = strong positive .

What controls should be included when validating a new ADRB3 antibody?

Proper validation of a new ADRB3 antibody requires a comprehensive set of positive and negative controls to ensure specificity and reliability of results. The following controls should be included:

Positive Controls:

• Cell lines with known ADRB3 expression: A549 and MCF-7 cells have been validated as positive controls for ADRB3 expression in Western blot applications

• Tissue samples: Adipose tissue (highest physiological expression), as well as specific cancer tissues known to overexpress ADRB3

• Recombinant ADRB3 protein: Can serve as a positive control in Western blot to confirm antibody specificity

Negative Controls:

• ADRB3 knockout or knockdown samples: Cells treated with ADRB3 siRNA can serve as negative controls

• Secondary antibody only: To detect non-specific binding of the secondary antibody

• Isotype control: Primary antibody of the same isotype but irrelevant specificity

• Tissues known to have minimal ADRB3 expression

Additional Validation Methods:

• Peptide competition assay: Pre-incubation of the antibody with the immunizing peptide should abolish specific staining

• Multiple antibody comparison: Use at least two antibodies raised against different epitopes of ADRB3

• Cross-validation: Compare results across multiple detection methods (WB, IF, IHC)

This comprehensive validation approach ensures that the observed signals are specific to ADRB3 and not due to non-specific binding or cross-reactivity with other proteins .

Why might Western blot analysis with ADRB3 antibodies show multiple bands or unexpected molecular weights?

Western blot analysis using ADRB3 antibodies sometimes yields multiple bands or bands at unexpected molecular weights, which can complicate data interpretation. This phenomenon can occur due to several factors:

• Post-translational modifications: ADRB3 undergoes various post-translational modifications including glycosylation and phosphorylation, which can alter its apparent molecular weight. While the calculated molecular weight of ADRB3 is approximately 51,990 Da, the observed molecular weight typically ranges from 44-50 kDa depending on the sample type and preparation conditions .

• Splice variants: Alternative splicing of the ADRB3 gene can generate protein isoforms of different molecular weights.

• Degradation products: Improper sample preparation or storage can lead to protein degradation, resulting in additional lower molecular weight bands.

• Cross-reactivity: Some antibodies may cross-react with other adrenergic receptors (ADRB1, ADRB2) due to sequence homology, particularly if using polyclonal antibodies.

To address these issues:

• Use freshly prepared samples with protease inhibitors

• Optimize sample preparation conditions (buffer composition, temperature)

• Consider using reducing vs. non-reducing conditions to account for disulfide bond effects

• Compare results with multiple antibodies targeting different epitopes

• Include appropriate positive controls (e.g., A549 or MCF-7 cells) where ADRB3 band patterns have been characterized

How can background signals be reduced in immunohistochemistry with ADRB3 antibodies?

High background is a common challenge when performing immunohistochemistry with ADRB3 antibodies. To reduce non-specific staining and improve signal-to-noise ratio, consider the following methodological optimizations:

• Blocking optimization:

  • Increase blocking time to 2 hours instead of standard 1 hour

  • Use 10% serum from the species in which the secondary antibody was raised (e.g., 10% goat serum)

  • Add 0.1-0.3% Triton X-100 to blocking solution to improve permeabilization

  • Consider adding 1% BSA to reduce non-specific binding

• Antibody dilution:

  • Optimize primary antibody dilution (1:200 has been validated, but titration may be necessary)

  • Reduce incubation temperature to 4°C with extended incubation time (overnight)

  • Prepare antibody dilutions in blocking buffer rather than PBS alone

• Washing steps:

  • Increase number and duration of washes (at least 3 × 10 minutes)

  • Add 0.05-0.1% Tween-20 to wash buffer to reduce non-specific binding

• Antigen retrieval:

  • Optimize antigen retrieval method (enzyme-based methods have been successful for ADRB3)

  • Compare heat-induced epitope retrieval vs. enzymatic methods

• Endogenous peroxidase/phosphatase blocking:

  • For DAB detection systems, thoroughly block endogenous peroxidase activity

  • For tissues with high endogenous biotin, use biotin-free detection systems

These optimizations have been successful in achieving clear staining patterns in tissue sections, allowing proper assessment of ADRB3 expression with minimal background interference .

What are the potential causes of false positive or false negative results when using ADRB3 antibodies?

Causes of False Positives:

• Cross-reactivity: ADRB3 antibodies may cross-react with other adrenergic receptors (ADRB1, ADRB2) due to sequence homology.

• Non-specific binding: Insufficient blocking or high antibody concentration can lead to non-specific binding.

• Endogenous enzyme activity: Inadequate blocking of endogenous peroxidases in IHC/ICC applications.

• Sample processing artifacts: Overfixation can create artificial epitopes that bind antibodies non-specifically.

• Detection system issues: Excessive development time in colorimetric assays can generate background signal.

Causes of False Negatives:

• Epitope masking: Fixation methods may alter or mask the ADRB3 epitopes recognized by the antibody.

• Insufficient antigen retrieval: ADRB3 epitopes may require specific retrieval methods to be accessible.

• Low expression levels: ADRB3 expression can vary significantly between tissues and cell types.

• Antibody degradation: Improper storage or handling of antibodies can reduce their reactivity.

• Protocol suboptimality: Inadequate incubation times or inappropriate buffer conditions.

Mitigation Strategies:

• Implement multiple validation controls (positive, negative, isotype controls)

• Use antibodies validated for specific applications (WB, ICC, IHC)

• Perform comparative analyses with different antibodies targeting distinct ADRB3 epitopes

• Include siRNA knockdown or CRISPR knockout controls

• Optimize each step of the protocol specifically for ADRB3 detection

• Confirm results using complementary techniques (e.g., RT-PCR, flow cytometry)

How can ADRB3 antibodies be utilized in cancer research applications?

ADRB3 antibodies have become valuable tools in cancer research due to the emerging role of beta-adrenergic signaling in tumor progression. These antibodies can be utilized in several sophisticated research applications:

• Prognostic biomarker assessment: ADRB3 expression has been identified as a poor prognostic factor in non-small cell lung cancer (NSCLC) and other malignancies. Immunohistochemical staining using validated ADRB3 antibodies enables researchers to correlate expression levels with patient outcomes. The recommended scoring system classifies staining as negative (0), equivocal (1), weak positive (2), or strong positive (3) .

• Tumor microenvironment studies: ADRB3 is expressed not only in cancer cells but also in tumor-associated macrophages (Mo-AMs). Dual immunofluorescence staining with ADRB3 antibodies and macrophage markers (e.g., CD68) can elucidate the role of adrenergic signaling in immune cell function within the tumor microenvironment .

• Therapeutic target validation: ADRB3-specific antagonists like SR59230A have shown anti-proliferative effects in cancer cell lines. Anti-ADRB3 monoclonal antibodies (e.g., M5D1) have demonstrated dose-dependent inhibition of cancer cell viability and increased apoptosis. These findings can be validated using ADRB3 antibodies in combination with proliferation markers (Ki-67) and apoptosis assays .

• Mechanistic studies: ADRB3 antibodies can be used to investigate downstream signaling pathways. Research has linked ADRB3 activation to mTOR pathway regulation, which can be studied using co-immunoprecipitation and co-localization experiments with ADRB3 and pathway component antibodies .

These applications demonstrate how ADRB3 antibodies contribute to understanding the complex role of adrenergic signaling in cancer biology and may lead to novel therapeutic strategies targeting this pathway.

What methodological approaches can enhance specificity when studying ADRB3 in tissues with low expression levels?

Detecting ADRB3 in tissues with low expression levels presents significant methodological challenges. To enhance specificity and sensitivity in such scenarios, researchers should consider the following advanced approaches:

• Signal amplification techniques:

  • Implement tyramide signal amplification (TSA) to amplify weak signals without increasing background

  • Use polymer-based detection systems that provide higher sensitivity than traditional ABC methods

  • Consider proximity ligation assay (PLA) for detecting protein-protein interactions involving ADRB3 with single-molecule sensitivity

• Sample preparation optimization:

  • Minimize fixation time to prevent epitope masking (4-8 hours in 4% PFA is often optimal)

  • Perform systematic comparison of different antigen retrieval methods (heat-induced vs. enzymatic)

  • Use fresh frozen samples when possible to preserve antigenicity

• Advanced microscopy techniques:

  • Employ super-resolution microscopy for subcellular localization studies

  • Use spectral unmixing to distinguish true signal from autofluorescence in tissues

  • Consider confocal microscopy with enhanced sensitivity detectors

• Complementary validation approaches:

  • Combine antibody detection with in situ hybridization to confirm mRNA expression

  • Use RNAscope to detect ADRB3 mRNA with single-molecule sensitivity

  • Employ laser capture microdissection to enrich specific cell populations before analysis

• Quantitative analysis methods:

  • Implement digital image analysis with machine learning algorithms for objective quantification

  • Use standardized positive controls with known expression levels for calibration

  • Consider flow cytometry or mass cytometry for quantitative single-cell analysis of ADRB3 expression

These methodological enhancements can significantly improve the detection of ADRB3 in challenging samples with low expression levels, enabling more reliable research outcomes.

How can ADRB3 antibodies be integrated into multiplexed immunoassays for comprehensive signaling pathway analysis?

Multiplexed immunoassays represent a powerful approach for analyzing ADRB3 in the context of complex signaling networks. Integrating ADRB3 antibodies into these systems requires careful consideration of several methodological aspects:

• Multiplex immunofluorescence optimization:

  • Select ADRB3 antibodies with minimal cross-reactivity to other adrenergic receptors

  • Use antibodies from different host species to enable simultaneous detection with other targets

  • Implement sequential staining protocols with tyramide signal amplification to enable multiple primary antibodies from the same host species

  • Carefully validate antibody panels to ensure no spectral overlap or steric hindrance

• Mass cytometry (CyTOF) integration:

  • Conjugate ADRB3 antibodies with rare earth metals not commonly used for other targets

  • Optimize metal conjugation ratios to achieve appropriate signal intensity

  • Include isotype controls conjugated with the same metal

  • Develop compensation matrices to account for signal spillover

• Protein array applications:

  • Use purified ADRB3 antibodies with validated specificity for reverse phase protein arrays

  • Implement appropriate blocking to minimize background in array formats

  • Include gradient controls of recombinant ADRB3 protein for quantification

• Single-cell western blot integration:

  • Optimize cell lysis conditions to maintain ADRB3 protein integrity

  • Determine appropriate antibody concentration for microfluidic-based single-cell westerns

  • Validate with ADRB3-expressing and non-expressing cell lines

• Data analysis considerations:

  • Implement unsupervised clustering algorithms to identify ADRB3-associated signaling patterns

  • Use dimensionality reduction techniques (t-SNE, UMAP) to visualize complex relationships

  • Develop computational approaches to quantify co-expression and signaling pathway activation

These approaches enable comprehensive analysis of ADRB3 signaling in the context of wider cellular signaling networks, providing deeper insights into its role in normal physiology and disease states.

How should researchers interpret discrepancies between ADRB3 antibody results and mRNA expression data?

Discrepancies between ADRB3 protein detection (via antibodies) and mRNA expression data are not uncommon and require careful interpretation. These discrepancies may arise from several biological and technical factors:

• Post-transcriptional regulation:

  • ADRB3 mRNA may be subject to miRNA-mediated repression, resulting in reduced protein expression despite high mRNA levels

  • mRNA stability factors can influence the correlation between transcript and protein levels

  • Alternative splicing may generate transcript variants that aren't detected by standard primers

• Post-translational regulation:

  • ADRB3 protein can undergo rapid degradation through ubiquitin-proteasome pathways

  • Receptor internalization and recycling dynamics affect membrane expression levels

  • Post-translational modifications may alter epitope availability for antibody recognition

• Technical considerations:

  • Different sensitivities of antibody-based methods versus RT-PCR or RNA-seq

  • Antibody specificity issues may lead to false positive or negative results

  • RNA extraction methods may preferentially isolate certain transcript variants

• Interpretative framework:

  • Consider temporal dynamics: mRNA expression often precedes protein expression

  • Evaluate subcellular localization: total protein versus membrane-localized receptor

  • Assess functional activity through downstream signaling markers alongside expression data

When facing such discrepancies, researchers should implement a multi-method validation approach:

• Confirm findings with multiple antibodies targeting different ADRB3 epitopes

• Use genetic manipulation (siRNA, CRISPR) to validate antibody specificity

• Employ subcellular fractionation to distinguish membrane-localized from total ADRB3

• Consider translational efficiency through polysome profiling

• Implement pulse-chase experiments to assess protein stability

Understanding these factors enables more accurate interpretation of seemingly contradictory results between protein and mRNA detection methods.

What challenges exist in quantifying ADRB3 expression levels across different experimental systems?

Quantifying ADRB3 expression levels across different experimental systems presents several significant challenges that researchers must address for reliable and comparable results:

• Standardization issues:

  • Lack of universal standards for ADRB3 quantification across different platforms

  • Variable antibody affinities affecting absolute quantification

  • Different detection sensitivities between instrument platforms

  • Inconsistent scoring systems in immunohistochemistry (e.g., 0-3+ vs. percentage positive)

• Technical variables:

  • Sample preparation differences (fixation methods, extraction buffers)

  • Variations in antigen retrieval protocols affecting epitope availability

  • Loading control selection and normalization approaches in Western blot

  • Threshold determination for positive vs. negative staining

• Biological variables:

  • Receptor density differences between cell types and tissues

  • Dynamic regulation of receptor expression under various conditions

  • Heterogeneity within samples (especially in tumor tissues)

  • Interspecies variations in ADRB3 structure affecting antibody recognition

• Methodological approaches to address these challenges:

  Method	Advantages	Limitations	Best Practices
  Western Blot	Semi-quantitative, good for relative comparisons	Limited spatial information	Include recombinant protein standard curve
  Flow Cytometry	Single-cell resolution, quantitative	Requires cell dissociation	Use calibration beads for absolute quantification
  IHC/ICC	Spatial context preserved	Subjective scoring	Implement digital image analysis with machine learning
  ELISA	Highly quantitative	Loses spatial information	Include standard curves with recombinant protein
  Mass Spectrometry	Absolute quantification possible	Complex sample preparation	Use isotope-labeled internal standards

• Recommended standardization approach:

  • Implement absolute quantification using recombinant ADRB3 standards

  • Report receptor density (receptors/cell) rather than arbitrary units

  • Use digital image analysis with validated algorithms for tissue samples

  • Include reference cell lines with known ADRB3 expression levels in each experiment

Addressing these challenges requires rigorous methodology and appropriate controls to ensure meaningful comparisons across different experimental systems.

How can researchers differentiate between ADRB3 isoforms or distinguish ADRB3 from other adrenergic receptors in complex samples?

Distinguishing ADRB3 from other adrenergic receptors and identifying specific ADRB3 isoforms represents one of the most challenging aspects of adrenergic receptor research. This differentiation requires sophisticated methodological approaches:

• Epitope mapping and antibody selection:

  • Use antibodies targeting unique epitopes in the C-terminal region or third intracellular loop of ADRB3, which show minimal homology with ADRB1 and ADRB2

  • For isoform discrimination, select antibodies recognizing specific splice variants

  • Validate antibody specificity using cells overexpressing individual receptor subtypes

  • Implement peptide competition assays with specific receptor peptides to confirm binding specificity

• Pharmacological approaches:

  • Combine antibody detection with selective ADRB3 agonists (e.g., CL316,243) or antagonists (e.g., SR59230A)

  • Observe changes in receptor localization or downstream signaling after selective stimulation

  • Use receptor activity-modifying proteins (RAMPs) that differentially affect receptor subtypes

• Genetic validation strategies:

  • Implement receptor subtype-specific siRNA knockdown to confirm antibody specificity

  • Use CRISPR/Cas9 to generate receptor knockout controls

  • Develop reporter constructs for specific isoforms with distinct tags

• Advanced analytical techniques:

  • Apply proximity ligation assay (PLA) with antibody pairs targeting different receptor domains

  • Implement super-resolution microscopy to visualize receptor clustering and co-localization

  • Use single-molecule tracking to distinguish receptor dynamics

• Mass spectrometry approaches:

  • Develop parallel reaction monitoring (PRM) assays targeting unique peptides

  • Implement crosslinking mass spectrometry to identify receptor-specific interactions

  • Use hydrogen-deuterium exchange mass spectrometry to determine structural differences

When none of these approaches alone provides definitive discrimination, researchers should implement a multi-method consensus approach, where concordance across several independent methods provides the strongest evidence for specific ADRB3 identification over other adrenergic receptors .

What are the emerging trends in ADRB3 antibody applications for precision medicine?

Emerging trends in ADRB3 antibody applications for precision medicine represent a rapidly evolving research frontier with significant translational potential. Several key developments are shaping this field:

• Companion diagnostics development:

  • ADRB3 antibodies are being evaluated as tools for patient stratification in clinical trials

  • Expression patterns in tumors may predict response to adrenergic-targeting therapies

  • Quantitative immunohistochemistry protocols are being standardized for clinical implementation

• Therapeutic antibody development:

  • Monoclonal antibodies targeting ADRB3 (like M5D1) have shown promising anti-cancer activity

  • Ongoing research focuses on optimizing antibody-drug conjugates targeting ADRB3

  • Bispecific antibodies linking ADRB3 recognition with immune cell activation are under investigation

• Liquid biopsy applications:

  • Detection of ADRB3-expressing circulating tumor cells using antibody-based capture

  • Antibody-based methods for detecting ADRB3 in exosomes as cancer biomarkers

  • Integration with other biomarkers for enhanced diagnostic accuracy

• Advanced imaging applications:

  • Development of ADRB3 antibody fragments for PET/SPECT imaging

  • Near-infrared fluorescence imaging with labeled antibodies for surgical guidance

  • Theranostic applications combining imaging and therapeutic capabilities

• Artificial intelligence integration:

  • Machine learning algorithms for automated quantification of ADRB3 staining patterns

  • AI-assisted prediction of therapy response based on ADRB3 expression patterns

  • Integration of multi-omics data with ADRB3 protein expression for patient classification

These emerging applications highlight the transition of ADRB3 antibodies from basic research tools to clinically relevant reagents with potential applications in cancer, metabolic disorders, and other conditions where adrenergic signaling plays a significant role .

What unresolved questions remain in ADRB3 antibody-based research?

Despite significant advances in ADRB3 antibody development and applications, several critical questions remain unresolved and represent important areas for future research:

• Epitope-function relationships:

  • How do different antibodies targeting distinct ADRB3 epitopes affect receptor function?

  • Can antibody binding to specific domains predict functional outcomes?

  • What is the relationship between antibody binding and receptor conformational states?

• Tissue-specific expression patterns:

  • What explains the discrepancies in ADRB3 detection across different tissues?

  • How does microenvironment influence antibody accessibility to ADRB3?

  • What are the precise subcellular localization patterns of ADRB3 in different cell types?

• Post-translational modifications:

  • How do glycosylation patterns affect antibody recognition of ADRB3?

  • Can antibodies be developed to specifically detect phosphorylated ADRB3?

  • What is the impact of ubiquitination and other modifications on epitope accessibility?

• Species cross-reactivity:

  • What structural differences explain variable antibody cross-reactivity between human, mouse, and rat ADRB3?

  • How can antibodies be optimized for consistent performance across species?

  • What are the implications of species differences for translational research?

• Methodological standardization:

  • What are the optimal fixation and preparation methods for ADRB3 detection in different applications?

  • How can quantification methods be standardized across laboratories?

  • What reference standards should be established for absolute quantification?

• Therapeutic antibody development:

  • Can antibodies be developed that selectively modulate specific ADRB3 signaling pathways?

  • What are the mechanisms by which anti-ADRB3 antibodies induce cancer cell apoptosis?

  • How can antibody penetration into solid tumors be optimized?